Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children
Publication date
2018-10
Authors
Bastiaans, Diane E. T.
Geelen, SPM
Visser, Eline G.
van der Flier, M.
Vermont, Clementien L.
Colbers, Angela P. H.
Roukens, Monique
Burger, David M.
van Rossum, Annemarie M. C.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
In this multicenter pharmacokinetic study in HIV-infected children (6–12 years of age), we validated the approved once-daily darunavir/ ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h·mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.
Keywords
Children, Darunavir, HIV, Once-daily, Pharmacokinetics, Taverne, Microbiology (medical), Infectious Diseases, Pediatrics, Perinatology, and Child Health
Citation
Bastiaans, D E T, Geelen, S P M, Visser, E G, van der Flier, M, Vermont, C L, Colbers, A P H, Roukens, M, Burger, D M & van Rossum, A M C 2018, 'Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children', Pediatric Infectious Disease Journal, vol. 37, no. 10, pp. 1008-1010. https://doi.org/10.1097/INF.0000000000001964